Trial Profile
A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Etoposide (Primary) ; Vorinostat (Primary)
- Indications CNS cancer; Hepatoblastoma; Liver cancer; Neuroblastoma; Rhabdomyosarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions; Therapeutic Use
- 08 Dec 2020 Status changed from active, no longer recruiting to completed.
- 25 Feb 2020 Planned End Date changed from 1 Feb 2020 to 1 Feb 2021.
- 25 Feb 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Feb 2021.